BioScrip Inc (NASDAQ:BIOS) has earned a consensus recommendation of “Hold” from the seven ratings firms that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $3.56.
BIOS has been the subject of several recent analyst reports. BidaskClub raised shares of BioScrip from a “hold” rating to a “buy” rating in a report on Thursday, January 4th. SunTrust Banks set a $4.00 price target on shares of BioScrip and gave the stock a “buy” rating in a report on Thursday, December 21st. Craig Hallum reissued a “buy” rating and issued a $3.50 price target on shares of BioScrip in a report on Thursday, March 8th. Zacks Investment Research raised shares of BioScrip from a “sell” rating to a “hold” rating in a report on Wednesday, January 10th. Finally, ValuEngine raised shares of BioScrip from a “sell” rating to a “hold” rating in a report on Thursday, November 30th.
Several institutional investors have recently added to or reduced their stakes in BIOS. Wells Fargo & Company MN grew its holdings in shares of BioScrip by 1.0% during the second quarter. Wells Fargo & Company MN now owns 114,810 shares of the company’s stock worth $312,000 after buying an additional 1,100 shares in the last quarter. Northern Trust Corp grew its holdings in shares of BioScrip by 11.3% during the second quarter. Northern Trust Corp now owns 1,340,339 shares of the company’s stock worth $3,639,000 after buying an additional 136,187 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of BioScrip by 3.4% during the second quarter. Vanguard Group Inc. now owns 4,495,029 shares of the company’s stock worth $12,204,000 after buying an additional 146,980 shares in the last quarter. Voya Investment Management LLC grew its holdings in shares of BioScrip by 41.4% during the second quarter. Voya Investment Management LLC now owns 50,799 shares of the company’s stock worth $138,000 after buying an additional 14,867 shares in the last quarter. Finally, State Street Corp grew its holdings in shares of BioScrip by 10.0% during the second quarter. State Street Corp now owns 1,815,439 shares of the company’s stock worth $4,927,000 after buying an additional 165,091 shares in the last quarter. 84.42% of the stock is owned by institutional investors and hedge funds.
BioScrip (NASDAQ:BIOS) last issued its quarterly earnings results on Thursday, March 8th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.07). The company had revenue of $182.50 million for the quarter, compared to the consensus estimate of $171.35 million. The business’s quarterly revenue was down 24.0% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.06) earnings per share. analysts expect that BioScrip will post -0.22 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “BioScrip Inc (BIOS) Given Average Recommendation of “Hold” by Brokerages” was originally reported by Markets Daily and is owned by of Markets Daily. If you are viewing this piece on another site, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The correct version of this piece can be viewed at https://www.themarketsdaily.com/2018/03/14/bioscrip-inc-bios-given-average-recommendation-of-hold-by-brokerages.html.
BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.